Buy Rating for Carisma Therapeutics Amid Expansion Into Autoimmune Treatments With Moderna Collaboration
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)
Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), 4D Molecular Therapeutics (FDMT) and Carisma Therapeutics (CARM)
CARISMA Therapeutics Analyst Ratings
CARISMA Therapeutics Analyst Ratings
Buy Rating Affirmed for Carisma Therapeutics Amid Progress in CAR-Monocyte Cancer Therapy
Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)
CARISMA Therapeutics Analyst Ratings
Buy Rating Affirmed for Carisma Therapeutics Amid Promising Cancer Treatment Developments
Buy Rating for Carisma Therapeutics: Innovative CAR-M Therapies Poised for Market Growth
Buy Rating on Carisma Therapeutics: Pioneering CAR-M Therapies in Oncology and Fibrosis
Analysts Are Bullish on These Healthcare Stocks: Neurocrine (NBIX), Carisma Therapeutics (CARM)
Buy Rating Affirmed: Promising Clinical Data and Strategic Shift Bolster Carisma Therapeutics' Outlook
Promising Future for Carisma Therapeutics' Cancer Immunotherapy: A Buy Rating Analysis
CARISMA Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)
Buy Rating Affirmed on Carisma Therapeutics Amid Promising Early Research and Pipeline Potential
CARISMA Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on CARISMA Therapeutics, Lowers Price Target to $9
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), Carisma Therapeutics (CARM) and Panbela Therapeutics (OtherPBLA)
No Data
No Data